FDA
-
-
-
-
-
-
-
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
-
-
-
-
-
-
-
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
-
-
-
-
-
-
-
Turning Point Therapeutics Inc. (TPTX) Outlines 2022 Clinical and Discovery Pipeline Milestones
-
-
-
-
-
-
-
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference
-
-
-
-
-
-
-
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
-
-
-
-
-
-
-
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
-
-
-
-
-
-
-
Turning Point Therapeutics (TPTX) Announces 2021 Milestone Targets
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

